A minireview: The role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm

Frontiers in Bioscience

Volumn 16, Issue 2, 2011, Pages 422-439

  Brzezianska, Ewa ^a   Pastuszak Lewandoska, Dorota ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Activating mutations; Epigenetic alteration; Gene amplification; MAPK ERK; PI3K Akt; Review; Signaling pathways; Thyroid Carcinoma

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; RAS PROTEIN;

CELL PROLIFERATION; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THYROID TUMOR;

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 79955015683     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3696     Document Type: Article

References (142)

1. Yu, G.P, J.C. Li, D. Branovan, S. McCormick & S.P. Schantz: Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 20, 465-473 (2010)
2. Sherma, S.I.: Thyroid carcinoma. Lancet 361, 501-511 (2003)
3. Slough, C.M. & G.W. Randolph: Workup of welldifferentiated thyroid carcinoma. Cancer Control 13, 99-105 (2006)
4. Rosai, J.: Poorly differentiated thyroid carcinoma: introduction to the issue, its landmarks, and clinical impact. Endocr Pathol 15, 293-296 (2004) (Pubitemid 40208908)
5. Nikiforov, Y.E.: Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15, 319-327 (2004) (Pubitemid 40208912)
6. Kondo, T., S. Ezzat & S.L. Asa: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6, 292-306 (2006)
7. Nishida, T., S. Katayama, M. Tsujimoto, J. Nakamura & H. Matsuda: Clinicopathological significance of poorly differentiated thyroid carcinoma. Am J Surg Pathol 23, 205-211 (1999) (Pubitemid 29075162)
8. Sobrinho-Simões, M., C. Sambade, E. Fonseca & P. Soares: Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol 10, 123-131 (2002) (Pubitemid 34655098)
9. Patel, K.N. & A.R. Shaha: Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13, 119-128 (2006)
10. Melillo, R. M., M. D. Castellone, V. Guarino, V. De Falco, A. M. Cirafici, G. Salvatore, F. Caiazzo, F. Basolo, R. Giannini, M. Kruhoffer, T. Orntoft, A. Fusco & M. Santoro: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115, 1068-1081 (2005) (Pubitemid 40489412)
11. Ciampi, R. & Y.E. Nikiforov: RET/PTC rearrangements and BRAF mutations in thyroid tumourigenesis. Endocrinology 148, 936-941 (2007)
12. MacCorkle, R.A. & T.H. Tan: Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 43, 451-461 (2005) (Pubitemid 41506881)
13. Lewis, T.S., P.S. Shapiro & N.G. Ahn: Signal transduction through MAP kinase cascades. Adv Cancer Res 74, 49-139 (1998) (Pubitemid 28193546)
14. Schlessinger, J.: Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000)
15. Kolch, W.: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351, 289-305 (2000)
16. Steelman, L.S., S.C. Pohnert, J.G. Shelton, R.A. Franklin, F.E. Bertrand & J.A. McCubrey: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18, 189-218 (2004) (Pubitemid 38240034)
17. McCubrey, J.A., L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, A. Tafuri, F. Stivala, M. Libra, J. Basecke, C. Evangelisti, A.M. Martelli & R.A. Franklin: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773, 1263-1284 (2007) (Pubitemid 47125967)
18. Farrar, M.A., J. Tjan & R.M. Perlmutter: Membrane localization of Raf assists engagement of downstream effectors. J Biol Chem 275, 31318-31324 (2000)
19. Fabian, J.R., I.O. Daar & D.K. Morrison: Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 13, 7170-7179 (1993) (Pubitemid 23321169)
20. Dhillon, A.S., S. Meikle, Z. Yazici, M. Eulitz & W. Kolch: Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J 21, 64-71 (2002) (Pubitemid 34087075)
21. Blagosklonny, M.V.: Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16, 455-462 (2002) (Pubitemid 34449725)
22. Peyssonnaux, C. & A. Eychene: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93, 53-62 (2001) (Pubitemid 33040860)
23. Pouyssegur, J., V. Volmat & P. Lenormand: Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64, 755-763 (2002) (Pubitemid 35238027)
24. Hwang, J.H., D.W. Kim, J.M. Suh, H. Kim, J.H. Song, E.S. Hwang, K.C. Park, H.K. Chung, J.M. Kim, T.H. Lee, D.Y. Yu & M. Shong: Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Mol Endocrinol 17, 1155-1166 (2003) (Pubitemid 36683722)
25. Nikiforov, Y. E.: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13, 3-16 (2002) (Pubitemid 34665111)
26. Pierotti, M.A., P. Vigneri & I. Bongarzone: Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res 154, 237-247 (1998)
27. Miller, F.D. & D.R. Kaplan : Neurotrophin signalling pathways regulating neuronal apoptosis. Cell Mol Life Sci 58, 1045-1053 (2001) (Pubitemid 32756515)
28. Ciampi, R., J.A. Knauf, R. Kerler, M. Gandhi, Z. Zhu, M.N. Nikiforova, H.M. Rabes, J.A. Fagin & Y.E. Nikiforov: Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115, 94-101 (2005) (Pubitemid 40385509)
29. Fukushima, T., S. Suzuki, M. Mashiko, T. Ohtake, Y. Endo, Y. Takebayashi, K. Sekikawa, K. Hagiwara & S. Takenoshita: BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22, 6455-6457 (2003) (Pubitemid 37281692)
30. Tallini, G. & S.L. Asa: RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 8, 345-354 (2001)
31. Santoro, M., R.M. Melillo, F. Carlomagno, A. Fusco & G. Vecchio: Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 963, 116-121 (2002) (Pubitemid 34721703)
32. Santoro, M., R.M. Melillo & A. Fusco: RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 155, 645-653 (2006) (Pubitemid 44857487)
33. Brzezianska, E., M. Karbownik, M. Migdalska-Sek, D. Pastuszak-Lewandoska, J. Wloch & A. Lewinski: Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat Res 599, 26-35 (2006) (Pubitemid 44041501)
34. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91, 3603-3610 (2006) (Pubitemid 44402144)
35. Knauf, J.A., H. Kuroda, S. Basu & J.A. Fagin: RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RASMAP kinase. Oncogene 22, 4406-4412 (2003) (Pubitemid 36897971)
36. Buckwalter, T.L., A. Venkateswaran, M. Lavender, K.M. La Perle, J.Y. Cho, M.L. Robinson & S.M. Jhiang: The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation. Oncogene 21, 8166-8172 (2002) (Pubitemid 35454419)
37. Fusco, A., G. Chiappetta, P. Hui, G. Garcia-Rostan, L. Golden, B.K. Kinder, D.A. Dillon, A. Giuliano, A.M. Cirafici, M. Santoro, J. Rosai & G. Tallini: Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 160, 157-167 (2002)
38. Powell, D.J. Jr, J. Russell, K. Nibu, G. Li, E. Rhee, M. Liao, M. Goldstein, W.M. Keane, M. Santoro, A. Fusco & J.L. Rothsteinl: The RET/PTC3 oncogene: metastatic solidtype papillary carcinomas in murine thyroids. Cancer Res 58, 5523-5528 (1998) (Pubitemid 28551140)
39. Santoro, M., G. Chiappetta, A. Cerrato, D. Salvatore, L. Zhang, G. Manzo, A. Picone, G. Portella, G. Santelli, G. Vecchio & A. Fusco: Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12, 1821-1826 (1996) (Pubitemid 26146307)
40. Soares, P. & M. Sobrinho-Simões: Correspondence re: G. Tallini et al., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotype. Clin. Cancer Res., 4:287-294, 1998.
41. Clin Cancer Res 11, 3724-3725 (1999)
42. Basolo, F., R. Giannini, C. Monaco, R.M. Melillo, F. Carlomagno, M. Pancrazi, G. Salvatore, G. Chiappetta, F. Pacini, R. Elisei, P. Miccoli, A. Pinchera, A. Fusco & M. Santoro: Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol 160, 247-254 (2002) (Pubitemid 34052285)
43. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM.. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 12, 2459-267 (1995)
44. Kim, D.W., H.K. Chung, K.C. Park, J.H. Hwang, Y.S. Jo, J. Chung, D.V. Kalvakolanu, N. Resta & M. Shong: Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Mol Endocrinol 21, 3039-3049 (2007) (Pubitemid 350223513)
45. Fan, D., C. Ma & H. Zhang: The molecular mechanisms that underlie the tumor suppressor function of LKB1. Acta Biochim Biophys Sin 41, 97-107 (2009)
46. Strazisar, M., V. Mlakar, T. Rott & D. Glavac: Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma. Cancer Invest 27, 407-416 (2009)
47. Ballhausen, W.G. & K. Günther: Genetic screening for Peutz-Jeghers syndrome. Expert Rev Mol Diagn 3, 471-479 (2003) (Pubitemid 36859294)
48. Castellone, M.D., V. De Falco, D.M. Rao, R. Bellelli, M. Muthu, F. Basaolo, A. Fusco, J.S. Gutkind & M. Santoro: The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res 69, 1867-1876 (2009)
49. Cassinelli, G., E. Favini, D. Degl'Innocenti, A. Salvi, G. De Petro, M.A. Pierotti, F. Zunino, M.G. Borrello & C. Lanzi: Neoplasm RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia 11, 10-21 (2009)
50. Cyniak-Magierska, A., E. Brzezianska, D. Pastuszak- Lewandoska, J. Januszkiewicz-Caulier & A. Lewinski: Increased expression of mRNA specific for c-Met oncogene in human papillary thyroid carcinoma. Arch Med Sci 3, 31-36 (2007) (Pubitemid 46640374)
51. Siraj, A.K., P. Bavi, J. Abubaker, Z. Jehan, M. Sultana, F. Al-Dayel, A. Al-Nuaim, A. Alzahrani, M. Ahmed, O. Al-Sanea, S. Uddin & K.S. Al-Kuraya: Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol 213, 190-199 (2007) (Pubitemid 47612241)
52. Miller, F.D. & D.R. Kaplan: On Trk for retrograde signaling. Neuron 32, 767-770 (2001) (Pubitemid 34024838)
53. Brzezianska, E., D. Pastuszak-Lewandoska & A. Lewinski: Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma. Neuro Endocrinol Lett 28, 221-229 (2007) (Pubitemid 47045763)
54. Butti, M.G., I. Bongarzone, G. Ferraresi, P. Mondellini, M.G. Borrello & M.A. Pierotti: A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 28, 15-24 (1995)
55. Russell, J.P., D.J. Powell, M. Cunnane, A. Greco, G. Portella, M. Santoro, A. Fusco & J.L. Rothstein: The TRKT1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 19, 5729-5735 (2000)
56. Teng, K.K. & B.L. Hempstead: Neurotrophins and their receptors: signaling trios in complex biological systems. Cell Mol Life Sci 61, 35-48 (2004) (Pubitemid 38121898)
57. Rocha, A.S., B. Risberg, J. Magalhães, V. Trovisco, I.V. de Castro, P. Lazarovici, P. Soares, B. Davidson & M. Sobrinho-Simões: The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Hum Pathol 37, 562-568 (2006)
58. Adjei, A.A.: Ras signaling pathway proteins as therapeutic targets. Curr Pharm Des 7, 1581-1594 (2001) (Pubitemid 32998572)
59. Vasko, V., M. Ferrand, J. Di Cristofaro, P. Carayon, J.F. Henry & C. de Micco: Specific pattern of RAS oncogene mutations in follicular thyroid tumours. J Clin Endocrinol Metab 88, 2745-2752 (2003) (Pubitemid 36724451)
60. Motoi, N., A. Sakamoto, T. Yamochi, H. Horiuchi, T. Motoi & R. Machinami : Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 196, 1-7 (2000) (Pubitemid 30046520)
61. Cyniak-Magierska, A., E. Brzezianska, J. Januszkiewicz-Caulier,B. Jarzab & A. Lewinski: Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS. Exp Clin Endocrinol Diabetes 115, 594-599 (2007) (Pubitemid 350070930)
62. Zhu, Z., M. Gandhi, M.N. Nikiforova, A.H. Fischer & Y.E. Nikiforov: Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120, 71-77 (2003) (Pubitemid 37046372)
63. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30, 216-222 (2006) (Pubitemid 43740191)
64. Monaco, C., D. Califano, G. Chiappetta, A. Mineo, V. De Franciscis, G. Vecchio & G. Santelli: Mutated human Kirsten ras, driven by a thyroglobulin promoter, induces a growth advantage and partially dedifferentiates rat thyroid epithelial cells in vitro. Int J Cancer 63, 757-760 (1995)
65. Portella, G., D. Vitagliano, C. Borselli, R.M. Melillo, D. Salvatore, J.L. Rothstein, G. Vecchio, A. Fusco & M. Santoro: Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol Res 11, 421-427 (1999)
66. Capella, G., X. Matias-Guiu, X. Ampudia, A. de Leiva, M. Perucho & J. Prat: Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragmentlength polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 5, 45-52 (1996)
67. Derwahl, M.: TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas - a note of caution. J Clin Endocrinol Metab 81, 2783-2785 (1996) (Pubitemid 26323863)
68. Garcia-Rostan, G., H. Zhao, R.L. Camp, M. Pollan, A. Herrero, J. Pardo, R. Wu, M.L. Carcangiu, J. Costa & G. Tallini: Ras mutations are associated with aggressive tumour phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21, 3226-3235 (2003) (Pubitemid 46606254)
69. Marais, R., Y. Light, H.F. Paterson, C.S. Mason & C.J. Marshall: Differential regulation of Raf-1, A-Raf and Braf by oncogenic ras and tyrosine kinases. J Biol Chem 272, 4378-4383 (1997) (Pubitemid 27078513)
70. Kumagai, A., H. Namba, S. Takakura, E. Inamasu, V.A. Saenko, A. Ohtsuru & S. Yamashita: No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma. Endocr J 53, 615-620 (2006) (Pubitemid 44691012)
71. Davies, H., G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton & P.A. Futreal: Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002) (Pubitemid 34716871)
72. Mitsutake, N., J.A. Knauf, S. Mitsutake, C. Mesa Jr, L. Zhang & J.A. Fagin: Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65, 2465-2473 (2005) (Pubitemid 40490159)
73. Xing, M.: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12, 245-262 (2005) (Pubitemid 40896444)
74. Kimura, E.T., M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov & J.A. Fagin: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63, 1454-1457 (2003) (Pubitemid 36373628)
75. 74.Trovisco, V., I. Vieira de Castro, P. Soares, V. Máximo, P. Silva, J. Magalhães, A. Abrosimov, X.M. Guiu & M. Sobrinho- Simões: BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202, 247-251 (2004) (Pubitemid 38208663)
76. Begum, S., E. Rosenbaum, R. Henrique, Y. Cohen, D. Sidransky & W.H. Westra: BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 17, 1359-1363 (2004) (Pubitemid 39472990)
77. Cohen, Y., M. Xing, E. Mambo, Z. Guo, G. Wu, B. Trink, U. Beller, W.H. Westra, P.W. Ladenson & D. Sidransky: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95, 625-627 (2003) (Pubitemid 36553510)
78. Ciampi, R. & Y.E. Nikiforov: Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16, 163-172 (2005) (Pubitemid 41687187)
79. Brzezianska, E., D. Pastuszak-Lewandoska, K. Wojciechowska, M. Migdalska-Sek, A. Cyniak-Magierska, E. Nawrot, A. Lewinski: Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett 28, 351-359 (2007) (Pubitemid 47577711)
80. Oler, G., K.N. Ebina, P. Michaluart Jr, E.T. Kimura & J. Cerutti: Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol 62, 509-511 (2005)
81. Trovisco, V., P. Soares, A. Preto, I.V. de Castro, J. Lima, P. Castro, V. Maximo, T. Botelho, S. Moreira, A.M. Meireles, J. Magalhaes, A. Abrosimov, J. Cameselle- Teijeiro & M. Sobrinho-Simoes: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446, 589-595 (2005) (Pubitemid 40922263)
82. Knauf, J.A., X. Ma, E.P. Smith, L. Zhang, N. Mitsutake, X.H. Liao, S. Refetoff, Y.E. Nikiforov & J.A. Fagin: Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65, 238-245 (2005)
83. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88, 4393-4397 (2003) (Pubitemid 37153748)
84. Nikiforova, M.N., E.T. Kimura, M.Gandhi, P.W. Biddinger, J.A. Knauf, F. Basolo, Z. Zhu, R. Giannini, G. Salvatore, A. Fusco, M. Santoro, J.A. Fagin & Y.E. Nikiforov: BRAF mutations in thyroid tumours are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88, 5399-5404 (2003) (Pubitemid 37452745)
85. Riesco-Eizaguirre, G., P. Gutierrez-Martinez, M.A. Garcia-Cabezas, M. Nistal & P. Santisteban: The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 13, 257-269 (2006)
86. Mesa Jr, C., M. Mirza, N. Mitsutake, M. Sartor, M. Medvedovic, C. Tomlinson, J.A. Knauf, G.F. Weber & J.A. Fagin: Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66, 6521-6529 (2006) (Pubitemid 44085606)
87. Fugazzola, L., D. Mannavola, V. Cirello, G. Vannucchi, M. Muzza, L. Vicentini & P. Beck-Peccoz: BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol 61, 239-243 (2004) (Pubitemid 39093120)
88. Kim, K.H., K.S. Suh, D.W. Kang & D.Y. Kang: Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 55, 540-545 (2005)
89. Fugazzola, L,. E. Puxeddu, N. Avenia, C. Romei, V. Cirello, A. Cavaliere, P. Faviana, D. Mannavola, S. Moretti, S. Rossi, M. Sculli, V. Bottici, P. Beck-Peccoz, F. Pacini, A. Pinchera, F. Santeusanio & R. Elisei: Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13, 455-464 (2006) (Pubitemid 43886668)
90. Soares, P., V. Trovisco, A. S. Rocha, J. Lima, P. Castro, A. Preto, V. Maximo, T. Botelho, R. Seruca & M. Sobrinho-Simoes: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22, 4578-4580 (2003) (Pubitemid 36920701)
91. Wan, P.T., M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, C.M. Jones, C.J. Marshall, C.J. Springer, D. Barford & R. Marais: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004) (Pubitemid 38410730)
92. Halilovic, E. & D.B. Solit: Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 8, 419-426 (2008)
93. Ciampi R, Zhu Z, Nikiforov YE. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol 16, 99-105 (2005) (Pubitemid 41400350)
94. Zheng, B., J.H. Jeong, J.M. Asara, Y.Y. Yuan, S.R. Granter, L. Chin & L.C. Cantley: Oncogenic B-RAF negatively regulates the tumour suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 30, 237-247 (2009)
95. Giordano, T.J., R. Kuick, D.G. Thomas, D.E. Misek, M. Vinco, D. Sanders, Z. Zhu, R. Ciampi, M. Roh, K. Shedden, P. Gauger, G. Doherty, N.W. Thompson, S. Hanash, R.J. Koenig & Y.E. Nikiforom: Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24, 6646-6656 (2005) (Pubitemid 41486795)
96. Puxeddu, E., S. Moretti, R. Elisei, C. Romei, R. Pascucci, M. Martinelli, C. Marino, N. Avenia, E.D. Rossi, G. Fadda, A. Cavaliere, R. Ribacchi, A. Falorni, A. Pontecorvi, F. Pacini, A. Pinchera & F. Santeusanio: BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89, 2414-2420 (2004) (Pubitemid 38619884)
97. Xu, X., R.M. Quiros, P. Gattuso, K.B. Ain, R.A. Prinz: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63, 4561-4567 (2003) (Pubitemid 36951030)
98. Castellone, M.D., A.M. Cirafici, G. De Vita, V. De Falco, L. Malorni, G. Tallini, J.A. Fagin, A. Fusco, R.M. Melillo & M. Santoro: Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene 22, 246-255 (2003) (Pubitemid 36174181)
99. Denning, K., P. Smyth, S. Cahill, J. Li, R. Flavin, S. Aherne, J.J. O' Leary & O. Sheils: ret/PTC-1 expression alters the immunoprofile of thyroid follicular cells. Mol Cancer 7, 44 (2008)
100. Cantley, L.C.: The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002) (Pubitemid 34579158)
101. García, Z., A. Kumar, M. Marqués, I. Cortés & A.C. Carrera: Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J 25, 655-661(2006) (Pubitemid 43292428)
102. Zhao L. & P.K. Vogt: Class I PI3K in oncogenic cellular transformation. Oncogene 27, 5486-5496 (2008)
103. Hennessy, B.T., D.L. Smith, P.T. Ram, Y. Lu & G.B. Mills: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4, 988-1004 (2005)
104. McCubrey, J.A., L.S. Steelman, S.L. Abrams, J.T. Lee, F. Chang, F.E. Bertrand, P.M. Navolanic, D.M. Terrian, R.A. Franklin, A.B. D'Assoro, J.L. Salisbury, M. Clorinda Mazzarino, F. Stivala & M. Libra: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46, 249-279 (2006) (Pubitemid 44301348)
105. Adjei, A.A. & M. Hidalgo: Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 23, 5386-5403 (2005) (Pubitemid 46206992)
106. Shinohara, M., Y.J. Chung, M. Saji & M.D. Singel: AKT in Thyroid Tumorigenesis and Progression. Endocrinology 148, 942-947 (2007)
107. Jiang, B.H. & L.Z. Liu: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Biochim Biophys Acta 1784, 150-158 (2008)
108. Blanco-Aparicio, C., O. Renner, J.F.M. Leal & A. Carnero: PTEN, more than the AKT pathway. Carcinogenesis 28, 1379-1386 (2007) (Pubitemid 47243536)
109. Byun, D.S., K. Cho, B.K. Ryu, M.G. Lee, J.I. Park, K.S. Chae, H.J. Kim & S.G. Chi: Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer 104, 318-327 (2003) (Pubitemid 36249814)
110. Lee, J.W., Y.H. Soung, S.Y. Kim, H.W. Lee, W.S. Park, S.W. Nam, S.H. Kim, J.Y. Lee, N.J. Yoo & S.H. Lee: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24, 1477-1480 (2005) (Pubitemid 40343128)
111. Levine, D.A., F. Bogomolniy, C.J. Yee, A. Lash, R.R. Barakat, P.I. Borgen & J. Boyd: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11, 2875-2878 (2005) (Pubitemid 40525186)
112. Wu, G., M. Xing, E. Mambo, X. Huang, J. Liu, Z. Guo, A. Chatterjee, D. Goldenberg, S.M. Gollin, S. Sukumar, B. Trink & D. Sidransky: Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7, R609-616 (2005)
113. Li, L., S.J. Plummer, C.L. Thompson, T.C. Tucker & G. Casey: Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res 14, 633-637 (2008) (Pubitemid 351231141)
114. Kuo, K.T., T.L. Mao, S. Jones, E. Veras, A. Ayhan, T.L. Wang, R. Glas, D. Slamon, V.E. Velculescu, R.J. Kuman & I.M. Shih: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174, 1597-1601 (2009)
115. García-Rostán, G., A.M. Costa, I. Pereira-Castro, G. Salvatore, R. Hernandez, M.J.A. Hermsem, A. Herrero, A. Fusco, J. Cameselle-Teijeiro & M. Santoro: Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer. Cancer Res 65, 10199-10207 (2005) (Pubitemid 41743711)
116. Philp, A.J., I.G. Campbell, C. Leet, E. Vincan, S.P. Rockman, R.H. Whitehead, R.J. Thomas & W.A. Phillips: The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61, 7426-7429 (2001) (Pubitemid 32995029)
117. Wu, G., E. Mambo, Z. Guo, S. Hu, X. Huang, S.M. Gollin, B. Trink, P.W. Ladenson, D. Sidransky & M. Xing: Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90, 4688-4693 (2005) (Pubitemid 41159359)
118. Vogt, P.K., S. Kang, M.A. Elsliger & M. Gymnopoulos: Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32, 342-349 (2007) (Pubitemid 47021415)
119. Ringel, M.D., N. Hayre, J. Saito, B. Saunier, F. Schuppert, H. Burch, V. Bernet, K.D. Burman, L.D. Kohn & M. Saji: Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61, 6105-6111(2001) (Pubitemid 32762546)
120. Nakayama, K., N. Nakayama, R.J. Kurman, L. Cope, G. Pohl, Y. Samuels, V.E. Velculescu, T.L Wan & I.M. Shih: Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5, 779-785 (2006) (Pubitemid 44775134)
121. Iamaroon, A. & S. Krisanaprakornkit: Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol 45, e175-e179 (2009)
122. Mure, H., K. Matsuzaki, K.T. Kitazato, Y. Mizobuchi, K. Kuwayama, T. Kageji & S. Nagahiro: Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol 12, 221-232 (2010)
123. Abbott, R.T., S. Tripp, S.L. Perkins, K.S.J. Elenitoba- Johnson & M.S. Lim: Analysis of the PI-3-Kinase-PTENAKT Pathway in Human Lymphoma and Leukemia Using a Cell Line Microarray. Mod Pathol 16, 607-612 (2003) (Pubitemid 36718443)
124. Terakawa, N., Y. Kanamori & S. Yoshida: Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 10, 203-208 (2003) (Pubitemid 36758649)
125. Sansal, I. & W.R. Sellers: The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway. J Clin Oncol 22, 2954-2963 (2004) (Pubitemid 41079915)
126. Hou, P., D. Liu, Y. Shan, S. Hu, K. Studeman, S. Condouris, Y. Wang, A. Trink, A.K. El-Naggar, G. Tallini, V. Vasko & M. Xing: Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer. Clin Cancer Res 13, 1161-1170 (2007) (Pubitemid 46424056)
127. Abubaker, J., Z. Jehan, P. Bavi, M. Sultana, S. Al- Harbi, M. Ibrahim, A. Al-Nuaim, M. Ahmed, T. Amin, M. Al-Fehaily, O. Al-Sanea, F. Al-Dayel, S. Uddin & K.S. Al- Kuraya: Clinicopathological Analysis of Papillary Thyroid Cancer with PIK3CA Alterations in a Middle Eastern Population. J Clin Endocrinol Metab 93, 611-618 (2008) (Pubitemid 351240838)
128. Mandal, M., S. Kim, M.N. Younes, S.A. Jasser, A.K. El-Naggar, G.B. Mills & J.N. Myers: The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92, 1899-1905B (2005)
129. Kim, C.F., V.V. Vasko, Y. Kato, M. Kruhlak, M. Saji, S-Y. Cheng & M.D. Ringel: AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 146, 4456-4463 (2005) (Pubitemid 41324044)
130. Vasko, V., M. Saji, E. Hardy, M. Kruhlak, A. Larin, V. Savchenko, M. Miyakawa, O. Isozaki, H. Murakami, T. Tsushima, K.D. Burman, C. De Micco & M.D. Ringel: Akt activation and localisation correlate with tumor invasion and oncogene expression in thyroid cancer. J Med Genet 41, 161-170 (2004) (Pubitemid 38333792)
131. Hou, P., M. Ji. & M. Xing: Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113, 2440-2447 (2008)
132. Liu, Z., P. Hou, M. Ji, H. Guan, K. Studeman, K. Jensen, V. Vasko, A. K. El-Naggar & M. Xing: Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers. J Clin Endocrinol Metab 93, 3106-3116 (2008)
133. Wang, Y., P. Hou, H. Yu, W. Wang, M. Ji, S. Zhao, S. Yan, X. Sun, D. Liu, B. Shi, G. Zhu, S. Condouris & M. Xing: High Prevalence and Mutual Exclusivity of Genetic Alterations in the Phosphatidylinositol-3-Kinase/Akt Pathway in Thyroid Tumors. J Clin Endocrinol Metab 92, 2387-2390 (2007) (Pubitemid 46997152)
134. Pilarski, R. & C. Eng: Will the real Cowden syndrome please stand up
135. Dahia, P.L., D.J. Marsh, Z. Zheng, J. Zedenius, P. Komminoth, T. Frisk, G. Wallin, R. Parsons, M. Longy, C. Larsson & C. Eng: Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57, 4710-4713 (1997) (Pubitemid 27468972)
136. Yeager, N., A. Klein-Szanto, S. Kimura & A. Di Cristofano: Pten Loss in the Mouse Thyroid Causes Goiter and Follicular Adenomas: Insights into Thyroid Function and Cowden Disease Pathogenesis. Cancer Res 67, 959-966 (2007)
137. Tell, G., A. Pines, F. Arturi, L. Cesaratto, E. Adamson, C. Puppin, I. Presta, D. Russo, S. Filetti & G. Damante: Control of phosphatase and tensin homolog (PTEN) gene expression in normal and neoplastic thyroid cells. Endocrinology 145, 4660-4666 (2004) (Pubitemid 39281459)
138. Alvarez-Nunez, F., E. Bussaglia, D. Mauricio, J. Ybarra, M. Vilar, E. Lerma, A. de Leiva & X. Matias-Guiu: PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16, 17-23 (2006) (Pubitemid 43346499)
139. Saito, J., A.D. Kohn, R.A. Roth, Y. Noguchi, I. Tatsumo, A. Hirai, K. Suzuki, L.D. Kohn, M. Saji & M.D. Ringel: Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 11, 339-351 (2001) (Pubitemid 32422626)
140. Gimm, O., A. Perren, L.P. Weng, D.J. Marsh, J.J. Yeh, U. Ziebold, E. Gil, R. Hinze, L. Delbridge, J.A. Lees, G.L. Mutter, B.G. Robinson, P. Komminoth, H. Dralle & C. Eng: Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156,1693-1700 (2000) (Pubitemid 30646707)
141. Xing, M.: Gene methylation in thyroid tumorigenesis. Endocrinology 148, 948-953 (2007)
142. Fagin, J.A.: Challenging dogma in thyroid cancer molecular genetics-role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 89, 4264-4266 (2004) (Pubitemid 39244423)